ReviewNeurobiology of stress2018
Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework.
Review in Neurobiology of stress, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Pharmacological stress impairs working memory performance and attenuates dorsolateral prefrontal cortex glutamate modulation.NeuroImage · 2019Trial
- Article
- Basal cortisol level modulates stress-induced opioid-seeking behavior.Neurobiology of stress · 2024Article
- A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders.Neuroscience applied · 2024Article
- Physical Exercise to Redynamize Interoception in Substance use Disorders.Current neuropharmacology · 2024Article
- Factors Associated with Relapses in Alcohol and Substance Use Disorder.The Eurasian journal of medicine · 2023Article
- Tapping into 5-HTInternational journal of molecular sciences · 2021Review
- Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking.Neurobiology of stress · 2021Review
- Review
- At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities.Translational research : the journal of laboratory and clinical medicine · 2021Review
- CRF-5-HT interactions in the dorsal raphe nucleus and motivation for stress-induced opioid reinstatement.Psychopharmacology · 2021Article
- Stress Allostasis in Substance Use Disorders: Promise, Progress, and Emerging Priorities in Clinical Research.Annual review of clinical psychology · 2020Review
- Pharmacotherapeutic management of co-morbid alcohol and opioid use.Expert opinion on pharmacotherapy · 2020Review
- Nuclear transcriptional changes in hypothalamus of Pomc enhancer knockout mice after excessive alcohol drinking.Genes, brain, and behavior · 2019Article
- Endocannabinoids and Fear-Related Behavior in Mice Selectively Bred for High or Low Alcohol Preference.Brain sciences · 2019Article
- Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.Molecules (Basel, Switzerland) · 2019Review
- Drug-induced stress responses and addiction risk and relapse.Neurobiology of stress · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for the most commonly abused substances). I evaluate neuropharmacological mechanisms in experimental models of drug-maintenance and relapse, which translate more readily to individuals presenting for treatment (who have initiated and progressed). An affective/motivational systems model (three dimensions: valence, arousal, control) is mapped onto a systems biology of addiction approach for addressing this problem. Based on quality of evidence to date, promising first-tier neurochemical receptor targets include: noradrenergic (α1 and β antagonist, α2 agonist),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.